Long term outcome of antiviral therapy in patients with hepatitis B associated decompensated cirrhosis

Table 2 Rate of clinical progression of liver disease

	Compensated chronic hepatitis B (n = 45683)									Decompensated cirrhosis (n = 2682)
	Newly decompensated incidence(n = 3401)			Hepatoma incidence(n = 5268)			Mortality incidence(n = 1415)			Second decompensated incidence(n = 1626)			Hepatoma incidence(n = 1295)			Mortality incidence(n = 874)
	Event	Percent	Accumulation (%)	Event	Percent	Accumulation (%)	Event	Percent	Accumulation (%)	Event	Percent	Accumulation (%)	Event	Percent	Accumulation (%)	Event	Percent	Accumulation (%)
< 1 yr	923	2.02%	2.02%	1602	3.51%	3.51%	253	0.55%	0.55%	1257	46.87%	46.87%	765	14.26%	14.26%	513	19.13%	19.13%
1-2 yr	662	1.45%	3.47%	1053	2.31%	5.81%	249	0.55%	1.10%	144	5.37%	52.24%	200	3.73%	17.99%	132	4.92%	24.05%
2-3 yr	634	1.39%	4.86%	947	2.07%	7.88%	280	0.61%	1.71%	99	3.69%	55.93%	140	2.61%	20.60%	94	3.50%	27.55%
3-4 yr	631	1.38%	6.24%	802	1.76%	9.64%	324	0.71%	2.42%	71	2.65%	58.58%	94	1.75%	22.35%	65	2.42%	29.98%
4-5 yr	551	1.21%	7.44%	864	1.89%	11.53%	309	0.68%	3.10%	55	2.05%	60.63%	96	1.79%	24.14%	70	2.61%	32.59%
aP for trend	< 0.0001			< 0.0001			0.0004			< 0.0001			< 0.0001			< 0.0001